Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta and Admera OncoGxSelect Diagnostics Panel

Rosetta Genomics and Admera Health have jointly launched OncoGxSelect diagnostics panel, a next-generation sequencing-based test that detects somatic mutations and provides actionable results. The new panel uses Admera Health's industry leading NGS technology and looks at 12 genes — ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, and ROS1 — commonly associated with lung cancer. It is a significant upgrade from the OncoGxLung, since it increase the number of genes examined from 5 to 12, and has the capacity to be used to diagnose other tumor types, Rosetta said. The test is a result of the 2014 marketing deal between Rosetta and Admera.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.